Contemporary Management of HIV: Antiretroviral Therapy As Prevention
Source: Contemporary Management of HIV

Slideset

Contemporary Management of HIV: Antiretroviral Therapy As Prevention

In this downloadable slideset, Kenneth Mayer, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for pre- and post-exposure prophylaxis in patients at risk for HIV infection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.46 MB
Date posted: 1/20/2017
  • What the iPrEX Study Taught Me About Adherence Counseling

    Kevin M. O'Hara MMSc, MS, PA-C - 10/24/2014    2 comments / Last Comment: 4/21/2015
    iPrEX OLE showed that perfect adherence was not required to attain the benefits of PrEP. How should that influence our approach to adherence counseling for our patients?
  • IAS 2015: A Preview of Key Data to Be Presented in Vancouver

    Chris Beyrer MD, MPH - 7/17/2015    6 comments / Last Comment: 8/3/2015
    Here is my take on the most anticipated studies that will be presented in Vancouver this year.
  • The Imperative for Women-Initiated HIV Prevention Technologies

    Quarraisha Abdool Karim PhD - 7/8/2016    1 comment / Last Comment: 7/11/2016
    Professor Quarraisha Abdool Karim, PhD, introduces her take on one of the key challenges for women at risk of HIV infection and evolving strategies for prevention. At an upcoming symposium in Durban, Catherine Hankins, MD, PhD, FRCPC, CM, and a multidisciplinary panel of experts will continue this discussion by providing their perspectives on 3 global challenges to treatment and prevention of HIV in women.
  • HSV-2 Prevention: An Unanticipated Benefit of Tenofovir-Based ART?

    Jeanne Marrazzo MD, MPH - 5/31/2013    
    Tenofovir/emtricitabine PrEP has been shown to decrease risk of HIV acquisition, but new data presented at CROI 2013 indicate it may decrease risk of HSV-2 infection as well.
  • What Does the IPERGAY Trial Tell Us About the Future of PrEP?

    Kevin M. O'Hara MMSc, MS, PA-C - 2/5/2015    2 comments / Last Comment: 4/3/2016
    Should on-demand dosing of oral PrEP become the new standard for HIV prevention among high-risk individuals?